RxDoctor Payments Data

An Lam

Nurse Practitioner · Gulfport, MSNPI 1457826067

Payments from drug & device makers

$3,791in general payments, 2019–2025

Across 154 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$781
  • Amgen$476
  • Fresenius USA Marketing, Inc.$285
  • Otsuka America Pharmaceutical, Inc.$272
  • Novartis$265
  • Nxstage Medical, Inc.$251
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,76599%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,791 in reported general payments places this provider in the 90th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$57,467
Medicare patients
263
Services billed
773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol61$47,026
RayaldeeCalcifediol16$35,290
VeltassaPatiromer Calcium Sorbitex27$30,419
JardianceEmpagliflozin22$26,459
AuryxiaFerric Citrate11$7,374
Midodrine Hcl23$1,504
Sevelamer Carbonate16$901
Hydralazine Hcl46$697
Potassium Chloride17$618
Allopurinol68$601
Calcitriol37$500
Pantoprazole Sodium17$394
Losartan Potassium50$360
Lisinopril47$284
Vitamin D2Ergocalciferol (Vitamin D2)37$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$781$47,02661 claims
OPKO Pharmaceuticals, LLCRayaldee$198$35,29016 claims
Boehringer IngelheimJardiance$52$26,45922 claims
Akebia Therapeutics IncAuryxia$146$7,37411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →